Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 42.7% in December

Exicure, Inc. (NASDAQ:XCUR) saw a significant decrease in short interest in December. As of December 31st, there was short interest totaling 139,368 shares, a decrease of 42.7% from the December 15th total of 243,112 shares. Approximately 4.6% of the shares of the stock are short sold. Based on an average daily volume of 82,461 shares, the days-to-cover ratio is currently 1.7 days. Based on an average daily volume of 82,461 shares, the days-to-cover ratio is currently 1.7 days. Approximately 4.6% of the shares of the stock are short sold.

Exicure Stock Up 4.2%

NASDAQ:XCUR opened at $6.25 on Friday. Exicure has a 52 week low of $3.10 and a 52 week high of $15.91. The stock’s fifty day moving average is $5.22 and its two-hundred day moving average is $5.49. The company has a market capitalization of $39.81 million, a P/E ratio of -1.69 and a beta of 4.06.

Exicure (NASDAQ:XCUR) last issued its quarterly earnings data on Friday, November 7th. The company reported ($0.39) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Exicure in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Insider Buying and Selling

In other news, major shareholder Sangsangin Investment & Securi sold 433,332 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $8.71, for a total value of $3,774,321.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 52.80% of the company’s stock.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.